Adverse effects
nausea, overdose, earache, mood instability, pain, dizziness, sleepiness, depression, Depression, irritability, DSM-5, cephalgia
ADVERSE EFFECTS, MAY, DISEASE PROGRESSION, ADVERSE EFFECTS
Adverse effects were mostly seen during and after active rTMS treatment. Of the 12 participants who experienced adverse effects, the effects were mild and temporary. These mainly included mild cephalgia, slight dizziness, nausea, sleepiness, transient earache, and pain at the site of stimulation. Only one participant in the ACC active-sham group experienced severe adverse effects (SAEs). This patient was on stable medication of quetiapine 500 mg and valproate 1000 mg per day and was excluded due to disease progression after 10 active rTMS sessions and two sham rTMS sessions. The patient was sent to the emergency room to have his stomach pumped on May 3, 2021, due to an overdose of about 20 pills (200 mg per pill) of quetiapine; he was discharged the following day and maintained on the same medication regimen until he went to the clinic on May 11, 2021. For several days after the overdose, the patient experienced mood instability, depression, and irritability with a score on the Chinese version of the Clinically Useful Depression Outcome Scale supplemented with DSM-5 Mixed subtype (CUDOS-M-C) of 19, which was much higher than the cut-off value of the standard of depression with mixed features [